Noninvasive testing for liver disease

May 1, 2021 12:10pm ‐ May 1, 2021 1:00pm

Identification: 25.2


BREAK

May 1, 2021 1:00pm ‐ May 1, 2021 1:10pm

Identification: 27


Decision Making in HCC Management

May 1, 2021 1:10pm ‐ May 1, 2021 1:35pm

Identification: 29.1

Presentation style: Case-based session with panel


Postoperative Crohn’s Disease: Where do we go now?

May 1, 2021 1:10pm ‐ May 1, 2021 1:35pm

Identification: 32.1

Presentation style: Case-based session with panel

Learning Objectives:
  • To understand the natural course of postoperative Crohn’s disease.
  • To describe the risk for recurrence after surgery and the medical options for prevention and treatment.
  • To review the postoperative Crohn's disease AGA guidelines.

Track A: Liver

May 1, 2021 1:10pm ‐ May 1, 2021 2:45pm

Identification: 29


Track B: IBD

May 1, 2021 1:10pm ‐ May 1, 2021 2:45pm

Identification: 32


Current and emerging treatment of NAFLD/NASH

May 1, 2021 1:35pm ‐ May 1, 2021 1:55pm

Identification: 29.2

Presentation style: Interview


Assessing and Managing Pouchitis

May 1, 2021 1:35pm ‐ May 1, 2021 1:55pm

Identification: 32.2

Presentation style: Interview

Learning Objectives:
  • Describe Normal Pouch Function
  • Review the assessment of pouch disorders
  • Understand the basic treatment approaches for pouchitis

Hepatitis B treatment 2021, guidance and pitfalls

May 1, 2021 1:55pm ‐ May 1, 2021 2:10pm

Identification: 29.3

Presentation style: Pitfall

Learning Objectives:
  • Define the goal of HBV functional cure
  • Describe several distinct classes of HBV antiviral therapy based on steps in the viral lifecycle
  • Describe recent data on novel antiviral agents for chronic hepatitis B

Choosing a Biologic in IBD

May 1, 2021 1:55pm ‐ May 1, 2021 2:10pm

Identification: 32.3

Presentation style: Pitfall

Learning Objectives:
  • To describe an individualized approach to choosing among the available biologic and advanced therapies for IBD
  • To interpret the evidence regarding appropriate sequencing of biologic and advanced therapies for IBD
  • To discuss the effect of COVID-19 on choice of biologic agents in IBD